Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic ATD
Time: 16:53:45
Mid Price: 18.00
Change Today: 0.00
Change % Today: -0.00
Fifty Two Week High: 28.50
Fifty Two Week Low: 15.00
Market Capital: 20.93
Period & price data
Period Price
Now: 18.00
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: LSE
Sector: Pharmaceuticals & Biotechnology
Epic: ATD
News: Latest news
Web Site: Asterand
Other Articles: 18-02-201009-02-201004-02-2010

Asterand

Asterand plc is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. Their mission is to provide human tissues and services to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success.

CLICK HERE FOR FULL ANLAYSIS OF ASTERAND
Tuesday, February 09, 2010

Daniel Stewart still sees 50% upside for Asterand shares, reiterates 'buy'

company news image

London-based stockbroker Daniel Stewart issued a note on human tissue and human tissue based services group Asterand (LSE: ATD), saying it still sees 50% upside for the share from the current level. The broker said that Asterand has a strong pipeline of business despite recent changes to buyer behaviour which has led to orders being spread over a longer period than planned.

In its trading update on 15 January, Asterand repeated its previous guidance on the industry’s changing customer behaviour. Among some of its customers, Asterand has noted that larger purchases are being split into smaller units to be bought over time.

The broker noted that contract research organisations world-wide are currently experiencing softer market demand in preclinical services, as pharmaceutical clients reprioritize their drug development pipelines and restructure their operations.

It has revised its target to 24 pence a share from 26p. Daniel Stewart maintains its 'buy' recommendation and still sees approximately 50% upside from current levels.

Asterand last week posted a circular relating to the planned acquisition of BioSeek Inc, which is to be approved by shareholders at a general meeting on 18 February.

The proposed acquisition of BioSeek will be Asterand's first step in its "buy and build" strategy to consolidate leadership in the global human tissue and human tissue based services market. It believes BioSeek is highly complementary to Asterand's business in terms of both products and services offered.

NewsNow icon AddThis Feed Button
Register here to be notified of future Asterand articles.

Other Asterand articles

More articles ►

Other Asterand news

More news ►

Investors interested in Asterand recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.